Cardiology / Preventive Medicine
Statin Initiation Decision Support
Adult cholesterol management workflow using the pooled-cohort treatment groups, risk-enhancing factors, CAC guidance, safety screening, and monitoring.
Clinical-use warning: this tool supports — but does not replace — clinical judgment, shared decision-making, medication reconciliation, contraindication screening, or an independently validated risk calculator. The pooled-cohort algorithm reflects older guidance; current dyslipidemia guidance favors PREVENT-based risk assessment.
1
Patient and high-risk groups
2
10-year risk and enhancers
Generally for adults 40–75 without clinical ASCVD and LDL-C 70–189 mg/dL. This tool does not calculate risk itself.
Risk-enhancing factors
3
CAC and safety considerations
Factors requiring caution, adjustment, or deferral
Recommendation
Complete the relevant fields, then select Generate recommendation.
Statin intensity reference
| Intensity | Common options | LDL-C reduction |
|---|---|---|
| High | Atorvastatin 40–80 mg Rosuvastatin 20–40 mg | ≥50% |
| Moderate | Atorvastatin 10–20 mg Rosuvastatin 5–10 mg Simvastatin 20–40 mg Pravastatin 40–80 mg | 30–49% |
| Low | Generally reserved for intolerance or special circumstances | <30% |